Nothing Special   »   [go: up one dir, main page]

Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 2, 2013

Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years

  • Ans H. Tiessen EMAIL logo , Willemein Jager , Nancy C.W. ter Bogt , Frank W. Beltman , Klaas van der Meer , Jan Broer and Andries J. Smit

Abstract

Background: Skin autofluorescence (SAF), as a proxy of AGE accumulation, is predictive of cardiovascular (CVD) complications in i.a. type 2 diabetes mellitus and renal failure, independently of most conventional CVD risk factors. The present exploratory substudy of the Groningen Overweight and Lifestyle (GOAL)-project addresses whether SAF is related to Systematic COronary Risk Evaluation (SCORE) risk estimation (% 10-year CVD-mortality risk) in overweight/obese persons in primary care, without diabetes/renal disease, and if after 3-year treatment of risk factors (change in, Δ) SAF is related to ΔSCORE.

Methods: In a sample of 65 participants from the GOAL study, with a body mass index (BMI) >25–40 kg/m2, hypertension and/or dyslipidemia, but without diabetes/renal disease, SAF and CVD risk factors were measured at baseline, and after 3 years of lifestyle and pharmaceutical treatment.

Results: At baseline, the mean SCORE risk estimation was 3.1±2.6%, mean SAF 2.04±0.5AU. In multivariate analysis SAF was strongly related to age, but not to other risk factors/SCORE. After 3 years ΔSAF was 0.34±0.45 AU (p<0.001). ΔSAF was negatively related to Δbodyweight but not to ΔSCORE%, or its components. At follow-up, SAF was higher in 11 patients with a history of CVD compared to 54 persons without CVD (p=0.002).

Conclusions: Baseline and 3-year-Δ SAF are not related to (Δ)SCORE, or its components, except age, in the studied population. ΔSAF was negatively related to Δweight. As 3-year SAF was higher in persons with CVD, these results support a larger study on SAF to assess its contribution to conventional risk factors/SCORE in predicting CVD in overweight persons with low-intermediate cardiovascular risk.


Corresponding author: Ans H. Tiessen, MD, Department of General Practice, FA 21, University Medical Center Groningen, P.O. Box 196, 9700 AD Groningen, The Netherlands, E-mail:

References

1. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324–30.10.1007/s00125-004-1451-2Search in Google Scholar PubMed

2. Meerwaldt R, Graaff R, Huisman RJ, Links TP, Thorpe SR, Baynes JW, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687–93.10.1681/ASN.2005020144Search in Google Scholar PubMed

3. den Hollander NC, Mulder DJ, Graaff R, Thorpe SR, Baynes JW, Smit GP, et al. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. J Inherit Metab Dis 2007;30:916–23.10.1007/s10545-007-0507-0Search in Google Scholar PubMed PubMed Central

4. Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:527–33.10.1097/MNH.0b013e32833e9259Search in Google Scholar PubMed

5. Januszewski AS, Sachithanandan N, Karschimkus C, O’Neal DN, Yeung CK, Alkatib N, et al. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 2012;29:726–33.10.1111/j.1464-5491.2011.03562.xSearch in Google Scholar PubMed

6. Lutgers HL, Graaff G, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Non-invasive AGE-measurements by skin autofluorescence in patients with type 2 diabetes mellitus. Tool for risk-assessment of diabetic complications? Diabetes Care 2006;29:2654–9.Search in Google Scholar

7. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637–44.10.1007/s00125-005-1828-xSearch in Google Scholar PubMed

8. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517–21.10.2337/dc07-1755Search in Google Scholar PubMed

9. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009;52:789–97.10.1007/s00125-009-1308-9Search in Google Scholar PubMed

10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.10.1056/NEJMoa0806470Search in Google Scholar PubMed

11. Münch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012;42:1221–36.10.1007/s00726-010-0777-ySearch in Google Scholar PubMed

12. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103–11.10.2337/diabetes.54.11.3103Search in Google Scholar PubMed PubMed Central

13. Chabroux S, Canouï-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010;36:152–7.10.1016/j.diabet.2009.11.003Search in Google Scholar PubMed

14. de Leeuw K, Graaff R, de Vries R, Dullaart RP, Smit AJ, Kallenberg CG, et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology 2007;46:1551–6.10.1093/rheumatology/kem215Search in Google Scholar PubMed

15. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011;6:2356–63.10.2215/CJN.02420311Search in Google Scholar PubMed PubMed Central

16. Hartog JW, Gross S, Oterdoom LH, van Ree RM, de Vries AP, Smit AJ, et al. Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation 2009;87:1069–77.10.1097/TP.0b013e31819d3173Search in Google Scholar PubMed

17. Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford) 2008;47:1554–8.10.1093/rheumatology/ken302Search in Google Scholar PubMed

18. de Leeuw K, Nienhuis H, Smit A, Stegeman C, Kallenberg C, Bijl M. Increased accumulation of advanced glycation endproducts in patients with Wegener’s granulomatosis. Ann Rheum Dis 2010;69:625–7.10.1136/ard.2009.123851Search in Google Scholar PubMed

19. Matsumoto T, Tsurumoto T, Baba H, Osaki M, Enomoto H, Yonekura A, et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int 2007;28:157–60.10.1007/s00296-007-0408-4Search in Google Scholar PubMed

20. Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, Graaff R, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2007;197:217–23.10.1016/j.atherosclerosis.2007.03.027Search in Google Scholar PubMed

21. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 2009;17:162–8.10.1007/BF03086239Search in Google Scholar PubMed PubMed Central

22. Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, Lutgers HL, et al. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging 2012;28:431–8.10.1007/s10554-011-9805-6Search in Google Scholar

23. de Vos LA, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, et al. Skin autofluorescence as a measure of advanced glycation end product deposition is elevated in peripheral artery disease. ATVB 2012. Available from: http://atvb.ahajournals.org/content/early/2012/11/08/ATVBAHA.112.300016. Accessed on November 27, 2012.Search in Google Scholar

24. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RP. Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 2010;40:812–7.10.1111/j.1365-2362.2010.02329.xSearch in Google Scholar

25. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.10.1016/S0195-668X(03)00114-3Search in Google Scholar

26. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain: one-year results of a randomized lifestyle intervention. Am J Prev Med 2009;37:270–7.10.1016/j.amepre.2009.06.011Search in Google Scholar PubMed

27. ter Bogt NC, Mulder IE, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, et al. Changes in lifestyle habits after counselling by nurse practitioners: 1-year results of the Groningen Overweight and Lifestyle study. Public Health Nutr 2011; 14:995–1000.10.1017/S1368980010003708Search in Google Scholar PubMed

28. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain by lifestyle intervention in a general practice setting: three-year results of a randomized controlled trial. Arch Intern Med 2011;171:306–13.10.1001/archinternmed.2011.22Search in Google Scholar PubMed

29. Noordzij MJ, Mulder DJ, Oomen PH, Brouwer T, Jager J, Castro Cabezas M, et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus – a multi-centre study. Diabet Med 2012;29:1556–61.10.1111/dme.12005Search in Google Scholar PubMed

30. Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008;23:67–74.10.1007/s10654-007-9204-4Search in Google Scholar PubMed

Received: 2012-11-29
Accepted: 2013-3-7
Published Online: 2013-04-02
Published in Print: 2014-01-01

©2014 by Walter de Gruyter Berlin Boston

Downloaded on 4.1.2025 from https://www.degruyter.com/document/doi/10.1515/cclm-2012-0825/html
Scroll to top button